
    
      This clinical study is designed as a phase 3,multicenter, double-blind, randomized,
      controlled study,to evaluate the efficacy and safety of nimotuzumab combined with TP compared
      with TP as first-line treatment for the metastatic esophageal squamous carcinoma.The main
      endpoint is OS.
    
  